BR9908215A - Derivados de ácidos hidroxâmico e carboxìlico - Google Patents

Derivados de ácidos hidroxâmico e carboxìlico

Info

Publication number
BR9908215A
BR9908215A BR9908215-2A BR9908215A BR9908215A BR 9908215 A BR9908215 A BR 9908215A BR 9908215 A BR9908215 A BR 9908215A BR 9908215 A BR9908215 A BR 9908215A
Authority
BR
Brazil
Prior art keywords
hydroxamic
derivatives
receptors
carboxylic acids
tnf
Prior art date
Application number
BR9908215-2A
Other languages
English (en)
Inventor
John Gary Montana
Andrew Douglas Baxter
David Alan Owen
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9802073.8A external-priority patent/GB9802073D0/en
Priority claimed from GBGB9819574.6A external-priority patent/GB9819574D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Publication of BR9908215A publication Critical patent/BR9908215A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Patente de Invenção:<B>''DERIVADOS DE áCIDOS HIDROXâMICO E CARBOXìLICO''<D>. Para o tratamento de câncer, inflamação ou outras condições associadas com as metaloproteinases de matriz ou que sejam mediadas por TNF<244> ou enzimas envolvidas no modificação de L-selectina, CD23, os receptores para TNF, os receptores para IL-1 ou os receptores para IL-6, os compostos são da fórmula geral (I) B-X-(CH~ 2~)~ m~-(CR¹R²)~ n~-W-COY.
BR9908215-2A 1998-01-30 1999-01-29 Derivados de ácidos hidroxâmico e carboxìlico BR9908215A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9802073.8A GB9802073D0 (en) 1998-01-30 1998-01-30 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
GBGB9819574.6A GB9819574D0 (en) 1998-09-08 1998-09-08 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
US09/239,603 US6100266A (en) 1998-01-30 1999-01-29 Hydroxamic and carboxylic acid derivatives
PCT/GB1999/000313 WO1999038843A1 (en) 1998-01-30 1999-01-29 Hydroxamic and carboxylic acid derivatives

Publications (1)

Publication Number Publication Date
BR9908215A true BR9908215A (pt) 2000-11-28

Family

ID=27269200

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9908215-2A BR9908215A (pt) 1998-01-30 1999-01-29 Derivados de ácidos hidroxâmico e carboxìlico

Country Status (18)

Country Link
US (1) US6100266A (pt)
EP (1) EP1051395B1 (pt)
JP (1) JP2002501943A (pt)
CN (1) CN100402496C (pt)
AT (1) ATE346041T1 (pt)
AU (1) AU735929B2 (pt)
BR (1) BR9908215A (pt)
CA (1) CA2317455C (pt)
CY (1) CY1106338T1 (pt)
DE (1) DE69934094T2 (pt)
DK (1) DK1051395T3 (pt)
ES (1) ES2277424T3 (pt)
HK (1) HK1029330A1 (pt)
HU (1) HUP0100597A3 (pt)
IL (1) IL137146A0 (pt)
NO (1) NO326266B1 (pt)
PL (1) PL200418B1 (pt)
WO (1) WO1999038843A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
CA2374460A1 (en) 1999-06-04 2000-12-14 Astrazeneca Ab Inhibitors of metalloproteinases
JP2003519119A (ja) * 1999-12-24 2003-06-17 スミスクライン ビーチャム パブリック リミテッド カンパニー （ヘテロ）ビシクリルメタンスルホニルアミノ置換ヒドロキサム酸誘導体
JP4256095B2 (ja) * 2000-02-21 2009-04-22 アストラゼネカ・アクチエボラーグ メタロプロテイナーゼの阻害剤としてのピペリジン−およびピペラジン置換ｎ−ヒドロキシホルムアミド類
WO2001062750A1 (en) * 2000-02-21 2001-08-30 Astrazeneca Ab Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp)
IL152990A0 (en) * 2000-05-25 2003-06-24 Smithkline Beecham Plc Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides
FR2827859B1 (fr) * 2001-07-30 2005-09-23 Lipha Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
GB0119474D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
GB0119473D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Compounds
GB0119472D0 (en) * 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
ES2319970T3 (es) 2001-09-07 2009-05-18 Kaken Pharmaceutical Co., Ltd. Derivados de acido hidroxamico inverso.
GB0128376D0 (en) * 2001-11-27 2002-01-16 Smithkline Beecham Plc Novel compounds
GB0128378D0 (en) * 2001-11-27 2002-01-16 Smithkline Beecham Plc Novel Compounds
SE0301922D0 (sv) 2003-06-27 2003-06-27 Astrazeneca Ab Novel compounds
WO2007060132A1 (en) * 2005-11-24 2007-05-31 Laboratoires Serono S.A. N-hydroxyamide derivatives and use thereof
US20100226922A1 (en) * 2006-06-08 2010-09-09 Dorothea Maetzel Specific protease inhibitors and their use in cancer therapy
US8765814B2 (en) * 2010-07-08 2014-07-01 Kaken Pharmaceutical Co., Ltd. N-hydroxyformamide derivative and medicament containing same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4267293A (en) * 1992-05-01 1993-11-29 British Biotech Pharmaceuticals Limited Use of MMP inhibitors
EP0826000B1 (en) * 1995-05-10 2002-10-23 Darwin Discovery Limited Peptide compounds which inhibit metalloproteinase and tnf liberation and their therapeutic uses
EP0994104A4 (en) * 1996-06-27 2001-09-12 Ono Pharmaceutical Co ARYL SULFIDE, SULFOXIDE AND SULPHONE DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING THEM AS AN ACTIVE INGREDIENT
UA48262C2 (uk) * 1996-09-27 2002-08-15 Фармація Енд Апджон Компані <font face="Symbol">b</font>-СУЛЬФОНІЛ ГІДРОКСАМОВІ КИСЛОТИ ЯК ІНГІБІТОРИ МАТРИЧНИХ МЕТАЛОПРОТЕЇНАЗ, ПРОМІЖНА СПОЛУКА ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ
US5962481A (en) * 1996-10-16 1999-10-05 American Cyanamid Company Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US6476027B1 (en) * 1997-03-04 2002-11-05 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
CN1178906C (zh) * 1997-07-31 2004-12-08 艾博特公司 基质金属蛋白酶的逆异羟肟酸盐抑制剂

Also Published As

Publication number Publication date
NO326266B1 (no) 2008-10-27
CY1106338T1 (el) 2011-10-12
CA2317455A1 (en) 1999-08-05
AU2291499A (en) 1999-08-16
ES2277424T3 (es) 2007-07-01
NO20003868D0 (no) 2000-07-28
DE69934094D1 (de) 2007-01-04
CN100402496C (zh) 2008-07-16
CA2317455C (en) 2011-01-25
IL137146A0 (en) 2001-07-24
NO20003868L (no) 2000-07-28
CN1289322A (zh) 2001-03-28
ATE346041T1 (de) 2006-12-15
WO1999038843A1 (en) 1999-08-05
EP1051395A1 (en) 2000-11-15
HUP0100597A3 (en) 2001-12-28
PL200418B1 (pl) 2009-01-30
JP2002501943A (ja) 2002-01-22
HUP0100597A2 (hu) 2001-08-28
DK1051395T3 (da) 2007-04-02
PL342184A1 (en) 2001-05-21
DE69934094T2 (de) 2007-06-06
US6100266A (en) 2000-08-08
AU735929B2 (en) 2001-07-19
HK1029330A1 (en) 2001-03-30
EP1051395B1 (en) 2006-11-22

Similar Documents

Publication Publication Date Title
BR9908215A (pt) Derivados de ácidos hidroxâmico e carboxìlico
EA200200058A1 (ru) Пиримидин-2,4,6-трионовые ингибиторы металлопротеиназ
CY1109328T1 (el) Ενωσεις θειενοδιβενζοαζουλενιου ως αναστολεις παραγοντα νεκρωσης ογκου
BR9808998A (pt) Imidazóis substituìdos úteis no tratamento de doenças inflamatórias
BR0308908A (pt) Composto, composição, uso de um composto, e, métodos para inibir a hdac em uma célula, para o tratamento de uma condição mediada pela hdac, de um condição proliferativa, de câncer e de psorìase
DK1465626T3 (da) Farmaceutiske præparater (kit) der omfatter dihydropyridinonforbindelser og et immunregulatorisk (eller et antiinflammatorisk) middel samt anvendelser deraf
EA200400595A1 (ru) Бензимидазолы, применяемые в качестве ингибиторов протеинкиназы
NZ523957A (en) 6.alpha., 9.alpha.-difluoro-17.alpha.-&#39;(2-furanylcarboxyl) oxy!-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4-diene-17-carbothioic acid S-fluoromethyl ester as an anti-inflammatory agent
BR0308967A (pt) Derivados de quinolina e isoquinolina, um processo para a sua preparação e sua aplicação como inibidores de inflamação
BG105880A (en) Compounds useful as anti-inflammatory agents
BRPI0507877A (pt) derivados de formamida, composição farmacêutica, uso dos mesmos e combinação
BR0208957A (pt) Ciclobuteno-1,2-dionas 3,4-dissubstituìdas como ligandos de receptor de quimiocina cxc
NO963499L (no) Hydroksaminsyre- og karboksylsyrederivater, fremgangsmåte for deres fremstilling og anvendelse derav
NO20063928L (no) Substituerte kinolinforbindelser
BR0309556A (pt) Inibidores de metaloproteinase pirimidina-2,4,6-triona
BR9912909A (pt) Derivados de ácido hidroxipipecolato hidroxâmico como inibidores de mmp
MEP25408A (en) Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same
BR0211502A (pt) Derivados de ácido acético de indano e seu uso como agentes farmacêuticos, intermediários, e método de preparação
NO20000784L (no) Nye aggrecanaseinhibitorer og matriksmetalloproteinaser for behandling av artritt
BRPI0415683A (pt) inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central
BR9813651A (pt) Compostos antipicornavirais e métodos para o seu uso e preparação
DE69905476T2 (de) Phosphonsaürederivate als ptp-1b-inhibitoren
BR0007589A (pt) Inibidores da proliferação de células
BR0210720A (pt) Composto e uso do mesmo
EA200500849A1 (ru) Новые соединения лапахона и способы их применения

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL.8: C07C 317/46, C07C 317/44, A61K 31/19, A61P 19/04, A61P 35/04

Ipc: C07C 317/44 (2008.01), C07C 317/46 (2008.01), A61K

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE ACORDO COM ART. 8O, 13 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.